Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
COVID-19
hepatocellular carcinoma
liver cancer
mortality
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
03
05
2022
received:
10
03
2022
accepted:
21
05
2022
pubmed:
25
5
2022
medline:
26
7
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
Sections du résumé
BACKGROUND & AIMS
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.
METHODS
Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.
RESULTS
Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection.
CONCLUSIONS
This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
Identifiants
pubmed: 35608939
doi: 10.1111/liv.15320
pmc: PMC9347559
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1891-1901Subventions
Organisme : Wellcome Trust
ID : PS3416
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 26813
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C9380/A26813
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C18342/A23390
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C9380/A18084
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
JHEP Rep. 2021 Jun;3(3):100260
pubmed: 33644725
Liver Int. 2022 Aug;42(8):1891-1901
pubmed: 35608939
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
JAMA Oncol. 2022 Jan 1;8(1):114-122
pubmed: 34817562
Dig Liver Dis. 2020 Sep;52(9):937-941
pubmed: 32703730
Lancet Oncol. 2021 Oct;22(10):1427-1437
pubmed: 34487693
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
HPB (Oxford). 2020 Aug;22(8):1128-1134
pubmed: 32565039
PLoS One. 2021 Aug 26;16(8):e0256544
pubmed: 34437610
BMJ Open. 2020 Nov 17;10(11):e043828
pubmed: 33203640
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19
pubmed: 32950749
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
J Hepatol. 2021 Oct;75(4):848-855
pubmed: 33992699
J Hepatocell Carcinoma. 2021 Sep 23;8:1159-1167
pubmed: 34589445
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630